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ABSTRACT 
 
Bradykinin is a key mediator of pain and inflammation. Although radiotherapy has proven to 
be beneficial in the treatment of inflammatory disorders, the effect of irradiation on the 
bradykinin pathway in human cells has not been evaluated yet. Therefore, the aim of the study 
was to establish a human cell culture system and to analyze bradykinin B2 receptor 
expression in response to different doses of gamma-ray exposure. Cultured human foreskin 
fibroblasts (HF15) were irradiated with 0.5 Gy, 2.0 Gy, 5.0 Gy and 10.0 Gy single doses 
using a Cobalt 60 radiation source. Before treatment (0h) as well as 6, 24, and 48 hours after 
radiation the bradykinin receptor surface density was quantified by a ligand binding assay 
using radioactive [3H]bradykinin. A dose and time dependant expression of the bradykinin B2 
receptor was observed. Initially, higher doses (2 and 10 Gy) induced a fast upregulation of the 
receptor, followed by long lasting downregulation compared to baseline levels. In contrast the 
lowest dose (0.5 Gy) induced a fast down regulation of the receptor. After 24 h and 48 h the 
levels increased again but remained below baseline levels. A dose- and time-dependant 
change in bradykinin B2 receptor expression on HF-15-cells in response to irradiation was 
demonstrated. The results may imply radio-biological explanations for the beneficial effect of 
radiotherapy in benign inflammatory diseases. 
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INTRODUCTION 
 
The nonapeptide bradykinin (NH2-Arg-Pro-
Pro-Gly-Phe-Ser-Pro-Phe-Arg-COOH), a 
prototypic member of the kinin family, is a 
key mediator in the initiation and 
maintenance of inflammatory processes 
(Kaplan et al., 2002). It is locally released on 
the surface of target cells due to limited 
proteolysis of their parental molecules, 
kininogens, by the kallikreins (Blaukat et al., 
2002) Its effects are transmitted via 
activation of the bradykinin B2 receptor 
(Regoli and Barabe, 1988) potentially 
leading to the formation of pro-inflammatory 
cytokines (e.g. IL-1 and TNF-α) as well as 
second generation mediators like platelet 
activating factor, leukotrienes, 
prostaglandins, and nitric oxide (Uknis et al., 
2001; Tiffany and Burch, 1989, Bareis et al., 
1983). In addition, bradykinin is able to 
either excite nociceptors directly or to 
sensitize them to mechanical or heat 
stimulation (Neugebauer et al., 1989; Kanaka 
 52
et al., 1985; Lang et al., 1990). In 
pathological states the multiplicity of 
biological effects can result in the cardinal 
signs of inflammation, namely tumor 
(edema), rubor, calor and dolor (Blaukat, 
2003; Cassim et al., 2002). Consequently the 
bradykinin pathway is considered to be 
involved in nearly all acute and chronic 
inflammatory diseases. Especially in 
inflamed joint diseases the importance of 
bradykinin and its correspondent B2 receptor 
is well documented (Cassim et al., 2002; 
Griesbacher et al., 2000, Stewart et al., 
1999). The injection of bradykinin induced 
acute arthritis in dogs (Lerner et al., 1987) 
and elevated kinin levels were found in 
patients with rheumatoid osteoarthritis (Bond 
et al., 1997, Jasani et al., 1989) The use of 
synthetic B2 receptor antagonists can 
effectively inhibit the release of pro-
inflammatory mediators and clinical 
symptoms (Mello et al., 2002; Uknis et al., 
2001; Burgess et al, 2000).  
 
Since the introduction of radiotherapy in 
clinical medicine in 1896 and during the first 
decades of the 20th century the treatment of 
benign inflammatory disorders with 
radiotherapy was a main domain of 
radiotherapists (Sokoloff, 1898; Leer et al., 
1998). However, after publications on 
potential induction of malignancies (Cour-
Brown et al., 1965; Lindelöf et al., 1986; van 
Daal et al., 1985) this option was discredited 
and consequently restricted to few 
indications, particularly in the Anglo-
American countries (Leer et al., 1998; 
Seegenschmidt et al., 2000). With the 
introduction of modern techniques, optimized 
schedules and smaller fields, the anti-
inflammatory and analgesic effects of low-
dose irradiation has again become a focus in 
clinical and research (Micke et al., 2002; 
Rödel et al; 2002). Although the biological 
mechanisms behind clinical improvement are 
poorly known, some recent studies revealed a 
significant modulation of important pro-
inflammatory molecules including cytokines 
and adhesion molecules (Rödel et al. 2002, 
Hildebrandt et al., 2002; 2000, 1998). 
 
Since there are no data available that 
elucidate the effects of low dose ionizing 
radiation on the bradykinin pathways, an in-
vitro model of cultured human fibroblasts 
was established and the expression of the 
bradykinin B2 receptor after irradiation with 
different doses at successive time points was 
analyzed. 
 
METHODS 
 
Cell Culture  
HF-15 human foreskin fibroblasts were 
grown to confluence in Dulbecco’s modified 
Eagle’s medium containing 10 % fetal calf 
serum, 1 % streptomycin-penicillin and 1 % 
L-glutamine for 2-3 weeks and used at 
passages 15-20 (Blaukat et al., 1996). 
 
Irradiation 
Cultured cells were irradiated using the 
gamma-rays (ca. 1.2 MeV) of a Cobalt 60 
treatment unit (Fa. Phillips, Germany) with 
single doses of 0.5 Gy, 2.0 Gy, 5.0 Gy and 
10.0 Gy. In order to compensate the build-up 
effect 5 mm water equivalent bolus material 
was used. Subsequently the cells were 
cultured for various time intervals (0, 6, 24, 
48 hours). All experiments were performed 
as triplicates. 
 
Ligand-binding-assay 
At time points 0, 6, 24, and 48 hours after 
radiation the bradykinin receptor density on 
the cell surface was measured. Membrane 
bradykinin B2 receptor expression was 
quantified by a ligand binding assay using 
radioactive [3H]bradykinin according to 
established procedures (Blaukat et al. 1996). 
In brief, cells were harvested in 20 mM 
PIPES, pH 6.8, 2 mM Bactitracinand 
collected by centrifugation at 310,000 g for 
30 min at 4 °C and used for ligand binding 
assays. Binding assays were performed by 
incubation with 5 nM [3H]bradykinin, 2 mM 
bacitracin in the same medium in the absence 
(total binding) or in the presence (nonspecific 
binding) of 5 µM unlabeled bradykinin for 
90 min at 4 C. The unbound ligand was 
removed by filtration trough flass fiber filters 
and 3x washes with 14 % isopropanol. Filter 
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and thus membrane bound [3H]bradykinin 
was quantified in a β-counter. 
 
Data analysis 
All experiments were performed as 
triplicates. Differences were calculated using 
the paired T-test. P-values below 0.05 were 
considered to be significant.  
 
RESULTS 
 
Time-dependent kinetic 
Bradykinin B2 receptor expression varied 
depending on the applied dose (figure 1). 
When high doses of radiation were used (10 
Gy, 2 Gy) the B2 receptor expression 
increased significantly to 136% and 123% 
from baseline (6h, p< 0.05). In contrast, 5 Gy 
irradiation showed no significant change 
after 6h (76 %), whereas low dose irradiation 
with 0.5 Gy induced a significant decrease to 
29%. The expression curves of the higher 
dose groups (10, 5, 2 Gy) declined after 24 h 
and where significantly lower after 48 h 
compared to baseline (62 %, 65 %, and 65 %, 
respectively, p < 0.05 0h versus 48h). In low 
dose (0.5 Gy) irradiated cells the B2 receptor 
was unregulated at the time point 24 h and 48 
h, but remained slightly but significantly 
below the baseline measurements (p< 0.05).  
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gure 1: Time course of bradykinin B2 receptor expression. 3H-bradykinin binding to 
man HF15 cells were measured before and after 6, 12, 24 and 48 h after radiation. Data 
ints present average and standard deviation of three experiments. 
se-dependent kinetic 
e most pronounced effect occurred after 6 
urs (figure 2). 0.5 Gy showed a significant 
crease, whereas 2 and 10 Gy showed a 
nificant increase in receptor expression. 
  time  point  48 h  there  was  a  consistent  
 
decrease of B2 receptor expression in cell 
samples treated with higher does of 
irradiation (2, 5, 10 Gy). The low dose 
treated cells (0.5 Gy) responded only with a 
modest non-significant decrease after 48 h. 
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Figure 2: Dose response of bradykinin B2 receptor expression. 3H-bradykinin binding to 
human HF15 cells were measured after the application of 0.5, 1.0, 2.0 and 5.0 Gy. Data points 
present average and standard deviation of three experiments. 
 
 
 
DISCUSSION 
 
The peptide hormone bradykinin and its 
corresponding B2 receptor are potent 
mediators of pain and inflammation (Kaplan 
et al., 2002). In particular in chronic 
inflammatory joint diseases increased levels 
of ligand or/and receptors were observed 
(Bond et al., 1997; Burgess et al., 2000; 
Cassim et al., 2002). This pilot study 
analyzed for the first time the influence of 
60Co γ-rays on bradykinin B2 receptor 
expression. In order to establish a well 
defined in vitro system without artificial 
transfection, the human fibroblast cell line 
HF15 which expresses the B2 receptor 
endogenously was chosen. The presented 
results indicate a dose and time dependent 
cell response to 60Co γ irradiation in respect 
to Bradykinin B2 receptor expression. Low 
dose irradiation with 0.5 Gy resulted in a 
marked decrease in receptor expression after 
a short time, which may be interpreted as 
marked inhibition of inflammatory response. 
Higher dose showed a tendency to increase 
expression in short term, which was followed 
by a time-dependent decrease well below 
baseline levels.  
 
 
The results correspond to molecular and 
clinical effects of low dose treatment in 
inflamed joint diseases. Low dose irradiation 
(total doses 2.5 Gy and 5 Gy with single 
doses of 0.5 resp. 1.0 Gy) lead to a long 
lasting reduction of the arthritis score in mice 
with adjuvant induced arthritis (Hildebrandt 
et al., 2000). The clinical effects went along 
with a significant reduction of iNOS 
(inducible nitric oxide synthetase), a pro-
inflammatory mediator, that can be induced 
by B2 receptor stimulation. In an arthritis 
rabbit model irradiation significantly reduced 
proliferation of synovial lining fibroblasts, 
production of synovial fluid and swelling of 
the knee joint (Budras et al., 1986). These 
anti-rheumatic effects could be reproduced in 
a variety of animal models with different 
types of inducible arthritis (Schurmann et al., 
1981; Trott et al., 1995; Fischer et al., 1994, 
1998). Interestingly, the application of the 
synthetic B2 receptor antagonist (HOE 140) 
revealed comparable - but faster - reduction 
of inflammatory markers like iNOS or 
Prostaglandin E2 (Mello et al., 2002) and an 
inhibition of bradykinin induced plasma 
extravasation and swelling in the arthritic 
joint (Cruwys et al., 1994; Sharma et al., 
1994). These findings along with the present 
study support the hypothesis that bradykinin 
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plays a key role in inflamed joint disease and 
may explain the beneficial effects of 
radiotherapy. 
 
Since the results indicate that the applied 
dose has a high impact on treatment response 
and duration, the observations may be of 
clinical interest. Our in vitro study is 
supported by the clinical observation that low 
dose irradiation (0.5 Gy) induced immediate 
anti-inflammatory response in arthritis of the 
hand. Yet, a long lasting inhibition of chronic 
inflammatory disorders was only achieved 
with higher fractionated total doses of 2 Gy 
and more applied on the other hand 
(Seegenschmidt et al., 2000). This might 
suggest that a dose of 0.5 Gy is more suitable 
in the therapy of acute inflammatory benign 
diseases. 
Nevertheless, since this study was initially 
planned as a pilot study including only 
limited amount of time points and doses, the 
results have to be interpreted with caution. A 
larger study design including more replicates 
and closer time points is clearly warranted. 
 
In conclusion we were able to demonstrate a 
dose- and time-dependant change in 
bradykinin receptor expression on HF-15-
cells in response to Co60-irradiation. The 
results may imply radio-biological 
explanations for the beneficial effect of 
radiotherapy in inflammatory diseases like 
inflamed or degenerative joint disease. 
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